Illumina, Inc.
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1998 |
| Founder | David R. Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, Mark Chee |
| Headquarters | San Diego , United States |
Area served | Worldwide (over 155 countries) |
Key people | Jacob Thaysen (CEO), Stephen P. MacMillan (Non-executive Chairman) |
| Products | Genetic sequencing and analysis systems, including DNA sequencing platforms (MiSeq, NextSeq 2000, NovaSeq X Series) |
| Website | www |
Illumina, Inc. is a biotechnology firm based in San Diego, California, United States. Established in 1998 by David R. Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee, Illumina specializes in creating and distributing comprehensive systems for examining genetic variation and biological processes. Its offerings cater to markets including sequencing, genotyping, gene expression, and proteomics, with a customer base spanning over 155 countries. Clients encompass genomic research institutions, pharmaceutical companies, academic organizations, clinical research groups, and biotechnology enterprises.
History
Illumina’s foundation traces back to technology licensed from Tufts University, with growth accelerated through acquisitions such as Spyder Instruments in 1999. The company became publicly traded in July 2000. In 2002, it introduced its inaugural genotyping platform, the Illumina BeadLab, subsequently expanding its range to include microarray-based genetic analysis products deployed worldwide.
In 2007, Illumina purchased the UK-based Solexa for roughly $650 million, acquiring next-generation sequencing technology developed at the University of Cambridge. This move considerably bolstered Illumina’s position within the genome sequencing sector. The acquisition also incorporated DNA colony sequencing techniques pioneered by Solexa.
The launch of the Personal Genome Sequencing Service occurred in 2009, followed by FDA clearance in 2010 for clinical application of the BeadXpress system—signaling Illumina’s strategic entry into clinical genetic diagnostics.
Growth continued with the 2011 acquisition of Epicentre Biotechnologies. In 2012, Illumina declined a $5.7 billion takeover offer from Hoffmann-La Roche; Roche subsequently withdrew after attempting to increase its bid.
By 2014, Illumina held a commanding 70% share of the genome-sequencing instrument market and was responsible for producing over 90% of global DNA data. The introduction of HiSeq X Ten enabled human genome sequencing at a groundbreaking cost of $1,000 per genome.
Leadership transitioned in 2016 when Francis deSouza succeeded Jay Flatley as CEO; Flatley assumed the role of executive chairman. The company had spun off Grail in 2015 to concentrate on blood-based cancer detection technologies; Grail attracted major investments from figures such as Bill Gates and Jeff Bezos. In 2020, Illumina announced plans to reacquire Grail for $8 billion.
In 2018, Illumina sought to acquire Pacific Biosciences for $1.2 billion but abandoned the transaction in 2020 due to regulatory obstacles imposed by the Federal Trade Commission (FTC). Similarly, the FTC filed suit to block Illumina’s $7.1 billion merger with Grail in 2021; despite opposition from regulators including the European Commission (EC), Illumina completed the acquisition but was subjected to fines and mandated divestitures.
September 2022 saw the release of NovaSeq X and NovaSeq X Plus sequencers capable of processing up to 20,000 genomes annually while offering improved data throughput and reagent stability at room temperature.
In mid-2023, deSouza stepped down as CEO; Charles Dadswell served as interim leader until Jacob Thaysen was appointed CEO in September 2023. Stephen P. MacMillan was named non-executive Chairman of the Board.
In October 2023, due to antitrust concerns, the EC ordered Illumina to divest Grail within twelve months; Illumina indicated intentions to pursue a sale through third parties or capital markets if legal appeals failed. By June 2024, Grail was spun off with Illumina retaining a minority interest of 14.5%. A 2024 appellate decision favored Illumina by ruling that the EC’s merger investigation exceeded its jurisdiction and annulled associated penalties.
Early in 2025, amid intensifying trade disputes, China placed Illumina on its "Unreliable Entities List" and prohibited exports of Illumina gene sequencers into China—posing considerable challenges to the company’s international operations and market penetration.
Acquisition history
The company's expansion approach involves a series of mergers, acquisitions, and divestitures, broadening its range of offerings and strengthening its market footprint:
- Illumina, Inc.
- Spyder Instruments (Acquired 1999)
- CyVera, Inc. (Acquired 2005)
- Solexa, Inc. (Acquired 2007)
- Solexa Ltd (Merged 2005)
- Lynx Therapeutics Inc. (Merged 2005)
- Avantome Inc. (Acquired 2008)
- Helixis, Inc. (Acquired 2010)
- Epicentre Biotechnologies (Acquired 2011)
- BlueGnome (Acquired 2012)
- Verinata Health, Inc. (Acquired 2013)
- Advanced Liquid Logic (Acquired 2013)
- NextBio (Acquired 2013)
- Myraqa (Acquired 2014)
- GenoLogics Life Sciences Software Inc. (Acquired 2015)
- Conexio Genomics (Acquired 2016)
- Edico Genome (Acquired 2018)
- Enancio (Acquired 2020)
- BlueBee (Acquired 2020)
- Emedgene (Acquired 2021)
- IDbyDNA (Acquired 2022)
- Partek Inc. (Acquired 2023)
- Fluent (Acquired 2024)
DNA sequencing
Illumina provides high-throughput DNA sequencing platforms utilizing technology originally developed by Solexa, which incorporates bridge amplification and reversible terminator chemistry to achieve accurate sequence reads. The process involves attaching fragmented DNA to a chip surface, adding primers, and then sequentially incorporating fluorescently labeled nucleotides for detection.
The MiSeq Series can produce up to 25 million reads per run, while the NextSeq 2000 employs dual flow cells to deliver as many as 2.4 billion single reads per run. The NovaSeq X Series stands at the forefront of the industry with a capacity of up to 52 billion single reads per run. Illumina's next-generation sequencing solutions provide substantial improvements in speed and efficiency compared to traditional Sanger methods, emphasizing short-read, image-based sequencing with exceptional accuracy—key factors driving its competitive edge in genomics.
Flow cells
Sequencing with Illumina technology takes place inside flow cells, compact devices situated within the flow cell compartment. The clustering process initiates when denatured DNA fragments are introduced and attach to primers fixed on the flow cell channels. DNA polymerase and nucleotides then synthesize complementary strands anchored to the flow cell surface. After washing away the original template strands, multiple cycles amplify each cluster to roughly 1,000 copies, enabling large-scale sequencing throughput.
Czarnik suit against Illumina
In 2005, Anthony Czarnik, co-founder and former Chief Scientific Officer, filed a lawsuit against Illumina regarding inventorship disputes. Although parts of the case were dismissed by the court, claims related to correcting inventorship were permitted to continue.
Cornell University and Life Technologies suit against Illumina
In 2010, Cornell University along with Life Technologies (now integrated into Thermo Fisher Scientific) initiated a patent infringement lawsuit targeting Illumina’s microarray product line. The case involved eight patents exclusively licensed to a start-up and was resolved in 2017 without any determination of fault. Later that same year, Cornell attempted to reopen the settlement by alleging that both Illumina and Life Technologies had misrepresented facts. Cornell asserted that Thermo Fisher had agreed to settle with Illumina and proposed modifications to patent claim language for pursuing additional litigation but instead settled another dispute and sublicensed patents without disclosure.
In 2018, Dr. Monib Zirvi brought forward a lawsuit accusing Illumina and certain key personnel of incorporating proprietary concepts and ZipCode DNA sequences from the Barany Lab into patent filings. This legal action was dismissed after Illumina contended that the statute of limitations barred these claims. Additionally, Dr. Zirvi submitted a FOIA request in 2020 seeking unredacted NIH grant documents essential to Illumina’s foundational development; it is notable that in 2015 Illumina’s attorney William Noon had filed an internal FOIA request for similar documentation.
Patent infringement litigation
Illumina has faced several patent-related legal battles that have influenced its strategic direction and market standing. In 2012, Verinata Health initiated litigation against rival Ariosa Diagnostics; after Illumina acquired Verinata in 2013, it became involved in the case. Ariosa filed a counterclaim, and although the initial verdict favored Ariosa, the Federal Circuit overturned this ruling. The conflict was ultimately settled prior to any Supreme Court review of the appeal.
In 2016, Illumina pursued legal action against Oxford Nanopore Technologies for alleged patent violations concerning the application of a biological nanopore (MspA) in sequencing technologies; the two companies reached a settlement within the same year.
In 2020, Illumina brought a patent infringement lawsuit against BGI Group related to its "CoolMPS" sequencing platforms. BGI responded by filing antitrust and unfair competition lawsuits, accusing Illumina of employing deceptive practices to enforce patents and hinder BGI’s entry into the U.S. market. By May 2022, a court ordered Illumina to compensate BGI’s U.S. subsidiary with $333 million for deliberate infringement of DNA sequencing patents, while simultaneously invalidating Illumina’s earlier claims against BGI.
Also in May 2022, a jury in Delaware determined that Illumina had willfully infringed two patents held by Complete Genomics, awarding damages near $334 million and invalidating three patents owned by Illumina. These judicial decisions carry considerable consequences for Illumina’s competitive position, financial results, and international sequencing operations.
Trade secrets lawsuit involving Eltoukhy and Talasaz
In March 2022, Illumina initiated legal proceedings against Helmy Eltoukhy and Amir Talasaz, founders of Guardant, accusing them of misappropriating trade secrets. Guardant dismissed these allegations as "baseless and retaliatory," attributing them to disputes over the Illumina-Grail acquisition and accusing Illumina of attempting to stifle competition within the industry.